title: [Efficacy and safety of the HAA regimen as induction chemotherapy in 236 de novo acute myeloid leukemia].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of the HAA regimen (homoharringtonine, cytarabine and aclarubicin) as induction chemotherapy in de novo acute myeloid leukemia (AML).
  
  
  METHODS
  The efficacy and safety of 236 de novo AML patients who received the HAA regimen as induction chemotherapy were retrospectively analyzed. The complete remission (CR) rate was assayed. Kaplan-Meier method was used to estimate overall survival (OS) and relapse free survival (RFS), and the differences were compared by Log-rank test.
  
  
  RESULTS
  The overall CR rate was 78.0%, and 65.7% of the patients attained CR in the first induction cycle. The early death rate was 4.7%. The median followup time was 41(1-161) months. The estimated 5-year OS and 5-year RFS rates were 44.9% and 45.5%, respectively. The CR rates of patients with favorable, intermediate and unfavorable cytogenetics were 92.9%,78.6%and 41.7%, respectively. The 5-year OS of favorable and intermediate group were 61.1% and 45.1%, respectively. The 5- year RFS of favorable and intermediate group were 49.0% and 45.4%, respectively. The median survival time of unfavorable group was only 5 months. The side effects associated with the HAA regimen were tolerable, in which the most common toxicities were myelosuppression and infection.
  
  
  CONCLUSIONS
  The HAA regimen is associated with a higher rate of CR and longer survival time and its toxicity could be tolerated.
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310001, China.
authors.forename: Pei-pei
authors.initials: PP
authors.lastname: Ye
authors.forename: Qi-tian
authors.initials: QT
authors.lastname: Mu
authors.forename: Fei-fei
authors.initials: FF
authors.lastname: Chen
authors.forename: Wen-yuan
authors.initials: WY
authors.lastname: Mai
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Meng
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Qian
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Tong
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.forename: Yin
authors.initials: Y
authors.lastname: Tong
authors.forename: Zhi-mei
authors.initials: ZM
authors.lastname: Chen
authors.forename: Ji-yu
authors.initials: JY
authors.lastname: Lou
authors.forename: Yun-gui
authors.initials: YG
authors.lastname: Wang
authors.forename: Wan-mao
authors.initials: WM
authors.lastname: Ni
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult